Evidence map›Paper›PMID 38662748›Full record

Observational studyPloS one2024

Predicting clinical outcomes of SARS-CoV-2 infection during the Omicron wave using machine learning.

Steven Cogill, Shriram Nallamshetty, Natalie Fullenkamp, Kent Heberer, Julie Lynch, Kyung Min Lee, Mihaela Aslan, Mei-Chiung Shih, Jennifer S Lee

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Steven CogillVA Palo Alto Cooperative Studies Program Coordinating Center, Palo Alto, CA, United States of America.
Shriram NallamshettyVA Palo Alto Cooperative Studies Program Coordinating Center, Palo Alto, CA, United States of America.ORCID 0000-0002-1256-5741
Natalie FullenkampVA Palo Alto Cooperative Studies Program Coordinating Center, Palo Alto, CA, United States of America.
Kent HebererVA Palo Alto Cooperative Studies Program Coordinating Center, Palo Alto, CA, United States of America.ORCID 0000-0003-2537-4335
Julie LynchVA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, United States of America.ORCID 0000-0003-0108-2127
Kyung Min LeeVA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, United States of America.
Mihaela AslanVA Clinical Epidemiology Research Center (CERC), VA Connecticut Healthcare System, West Haven, CT, United States of America.
Mei-Chiung ShihVA Palo Alto Cooperative Studies Program Coordinating Center, Palo Alto, CA, United States of America.
Jennifer S LeeVA Palo Alto Cooperative Studies Program Coordinating Center, Palo Alto, CA, United States of America.ORCID 0000-0003-2466-2730
VA Palo Alto Health Care System · USStanford University · USUniversity of Utah · USVA Salt Lake City Healthcare System · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Omicron SARS-CoV-2 variant continues to strain healthcare systems. Developing tools that facilitate the identification of patients at highest risk of adverse outcomes is a priority. The study objectives are to develop population-scale predictive models that: 1) identify predictors of adverse outcomes with Omicron surge SARS-CoV-2 infections, and 2) predict the impact of prioritized vaccination of high-risk groups for said outcome. We prepared a retrospective longitudinal observational study of a national cohort of 172,814 patients in the U.S. Veteran Health Administration who tested positive for SARS-CoV-2 from January 15 to August 15, 2022. We utilized sociodemographic characteristics, comorbidities, and vaccination status, at time of testing positive for SARS-CoV-2 to predict hospitalization, escalation of care (high-flow oxygen, mechanical ventilation, vasopressor use, dialysis, or extracorporeal membrane oxygenation), and death within 30 days. Machine learning models demonstrated that advanced age, high comorbidity burden, lower body mass index, unvaccinated status, and oral anticoagulant use were the important predictors of hospitalization and escalation of care. Similar factors predicted death. However, anticoagulant use did not predict mortality risk. The all-cause death model showed the highest discrimination (Area Under the Curve (AUC) = 0.903, 95% Confidence Interval (CI): 0.895, 0.911) followed by hospitalization (AUC = 0.822, CI: 0.818, 0.826), then escalation of care (AUC = 0.793, CI: 0.784, 0.805). Assuming a vaccine efficacy range of 70.8 to 78.7%, our simulations projected that targeted prevention in the highest risk group may have reduced 30-day hospitalization and death in more than 2 of 5 unvaccinated patients.

Indexed as

COVID-19HospitalizationMachine LearningSARS-CoV-2AdultAgedAged, 80 and overComorbidityCOVID-19 VaccinesFemaleHumansLongitudinal StudiesMaleMiddle AgedRetrospective StudiesVaccinationCOVID-19 Vaccines

Identifiers

PMID38662748
PMCPMC11045098
OpenAlexW4395448050

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.